The European Wellness Biomedical Group (EW Group), through its Malaysian subsidiary European Wellness Academie, and Dubai-based healthcare distribution and technology group, AK International, have partnered to strengthen medical and wellness tourism linkages, particularly for the management of chronic degenerative conditions and untreatable rare diseases.
EW Group is seeking to scale up adoption of German and Swiss medical cell-based bio-therapeutic techniques for the management of chronic degenerative conditions and untreatable rare diseases.
The partnership with AK International will create two centres of excellence in the UAE, one specialising in the rehabilitation, education and holistic management of paediatric and neurodegenerative neuro developmental disorders such as Autism Spectrum Disorder, Cerebral Palsy, Down Syndrome and Global Developmental Delay; and another specialising in the management of untreatable and rare diseases such as CHARGE Syndrome, Multiple Sclerosis, Rheumatoid Arthritis, and Parkinson’s Disease.
The UAE centres will also provide local patients seeking biological regenerative medicine solutions with access to a case referral network worldwide from initial inquiry to preliminary medical investigation, to assisted medical travel, and follow-up care.
EW Group owns and operates a network of 26 hospital and medical centres specialising in regenerative biomedicine and luxury wellness centres.
The partnership will also look to develop a technology-driven digital wellness service ‘corridor’, to seamlessly connect UAE patients with healthcare service providers in Malaysia.
The partnership will also explore potential investment into the Iskandar Malaysia Development Area in Johor, to develop a Halal Hub for Biotechnology and Regenerative Medicine. The 100-bed integrative medicine hospital will be modelled after EW Group’s medical facility in Germany, with Muslim centred aged care retirement villas and assisted living apartments, and a GMP-certified halal biologics and botanical drug manufacturing facility.
EW Group focuses on organ-specific precursor (progenitor) stem cell therapeutics, biological and synthetic peptides, biological regenerative medicine, immunotherapies, nutraceuticals and cosmeceuticals.
The group is headquartered in Germany and Malaysia, with research and biopharmaceutical manufacturing facilities in Germany, Switzerland, United States, Czech Republic, and the United Kingdom.